Media

Oncopeptides – Annual General Meeting in Oncopeptides

Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting 2026

Kivu Bioscience Appoints Mohit Trikha, Ph.D., as Chief Executive Officer

Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline

Intervacc publishes the 2025 Annual Report

SynOx Therapeutics announces positive topline results from the Phase 3 TANGENT study

Preclinical data on novel NK-Cell engager to be presented at the AACR Annual Meeting 2026

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Number of shares and votes in Oncopeptides

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial